Company intelligence / Profile preview
Erasca
San Diego, California, United Stateserasca.com ↗
- Ownership
- Public · ERAS
- Employees
- ~103
- Development stage
- Phase 2
01
Overview
Clinical-stage precision oncology company developing RAS/MAPK pathway inhibitors. Lead candidate naporafenib in Phase3 for NRASm melanoma. Multiple early-stage assets targeting KRAS/RAS mutants and EGFR-driven cancers[1][4][7]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
Novartis(naporafenib license)[4]Katmai Pharmaceuticals(ERA-SA801)[45]NiKang Therapeutics(ERA-SA601)[45]
04
Financials
- Market cap
- $5.6B
- Total revenue
- $0
- Enterprise value
- $5.3B
Beyond the preview
Go deeper on Erasca.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erasca.